KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-02-01

AUTHORS

Da Meng, Richard D. Carvajal

ABSTRACT

Metastatic melanoma is a heterogenous disease that has served as a model for the development of both targeted therapy and immunotherapy. KIT-mutated melanoma represents a rare subset, most commonly arising from acral, mucosal, and chronically sun-damaged skin. Additionally, KIT alterations are enriched in the triple wild-type subtype of cutaneous melanoma. Activating alterations of KIT—a transmembrane receptor tyrosine kinase important for cell development, growth, and differentiation—have been shown to be critical to oncogenesis across many tumor subtypes. Following the successes of BRAF-targeted therapy in melanoma and KIT-targeted therapy in gastrointestinal stromal tumors, small-molecule tyrosine kinase inhibitors targeting KIT have been examined in KIT-mutated melanoma. KIT inhibitors that have been investigated in relevant clinical trials in advanced melanoma include imatinib, sunitinib, dasatinib, and nilotinib. In these studies, selected patients with KIT-mutated melanoma were shown to be responsive to therapy with KIT inhibition, especially patients with L576P and K642E mutations. This has led to the incorporation of KIT-targeted therapy in the National Comprehensive Cancer Network guidelines for systemic therapy for metastatic or unresectable melanoma. Current research and development efforts include novel KIT-targeted therapies and testing KIT inhibitors in combination with immunotherapy. More... »

PAGES

315-323

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40257-018-0414-1

DOI

http://dx.doi.org/10.1007/s40257-018-0414-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111836770

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30707374


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Immunological", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dermatology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Medical Oncology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Molecular Targeted Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Practice Guidelines as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-kit", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Skin Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.21729.3f", 
          "name": [
            "Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meng", 
        "givenName": "Da", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center and the Herbert Irving Comprehensive Cancer Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.516091.a", 
          "name": [
            "Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center and the Herbert Irving Comprehensive Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carvajal", 
        "givenName": "Richard D.", 
        "id": "sg:person.0726366600.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nature22071", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085123990", 
          "https://doi.org/10.1038/nature22071"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-010-0692-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016450622", 
          "https://doi.org/10.1007/s12185-010-0692-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2010.11", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046949857", 
          "https://doi.org/10.1038/leu.2010.11"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2009.46", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012226579", 
          "https://doi.org/10.1038/leu.2009.46"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40425-017-0238-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084612708", 
          "https://doi.org/10.1186/s40425-017-0238-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/373347a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050917690", 
          "https://doi.org/10.1038/373347a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature11071", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015512980", 
          "https://doi.org/10.1038/nature11071"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng.2359", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021618497", 
          "https://doi.org/10.1038/ng.2359"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00018-004-4189-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015934344", 
          "https://doi.org/10.1007/s00018-004-4189-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature00766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023536940", 
          "https://doi.org/10.1038/nature00766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2438", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005333082", 
          "https://doi.org/10.1038/nm.2438"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng.3382", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041262840", 
          "https://doi.org/10.1038/ng.3382"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-02-01", 
    "datePublishedReg": "2019-02-01", 
    "description": "Metastatic melanoma is a heterogenous disease that has served as a model for the development of both targeted therapy and immunotherapy. KIT-mutated melanoma represents a rare subset, most commonly arising from acral, mucosal, and chronically sun-damaged skin. Additionally, KIT alterations are enriched in the triple wild-type subtype of cutaneous melanoma. Activating alterations of KIT\u2014a transmembrane receptor tyrosine kinase important for cell development, growth, and differentiation\u2014have been shown to be critical to oncogenesis across many tumor subtypes. Following the successes of BRAF-targeted therapy in melanoma and KIT-targeted therapy in gastrointestinal stromal tumors, small-molecule tyrosine kinase inhibitors targeting KIT have been examined in KIT-mutated melanoma. KIT inhibitors that have been investigated in relevant clinical trials in advanced melanoma include imatinib, sunitinib, dasatinib, and nilotinib. In these studies, selected patients with KIT-mutated melanoma were shown to be responsive to therapy with KIT inhibition, especially patients with L576P and K642E mutations. This has led to the incorporation of KIT-targeted therapy in the National Comprehensive Cancer Network guidelines for systemic therapy for metastatic or unresectable melanoma. Current research and development efforts include novel KIT-targeted therapies and testing KIT inhibitors in combination with immunotherapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40257-018-0414-1", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1021743", 
        "issn": [
          "1175-0561", 
          "1179-1888"
        ], 
        "name": "American Journal of Clinical Dermatology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "keywords": [
      "National Comprehensive Cancer Network guidelines", 
      "KIT inhibitors", 
      "small molecule tyrosine kinase inhibitors", 
      "gastrointestinal stromal tumors", 
      "relevant clinical trials", 
      "tyrosine kinase inhibitors", 
      "systemic therapy", 
      "unresectable melanoma", 
      "advanced melanoma", 
      "stromal tumors", 
      "Network guidelines", 
      "metastatic melanoma", 
      "cutaneous melanoma", 
      "heterogenous disease", 
      "clinical trials", 
      "rare subset", 
      "tumor subtypes", 
      "clinical development", 
      "therapy", 
      "oncogenic drivers", 
      "melanoma", 
      "KIT alterations", 
      "transmembrane receptor tyrosine kinase", 
      "receptor tyrosine kinases", 
      "KIT inhibition", 
      "kinase inhibitors", 
      "immunotherapy", 
      "novel kit", 
      "patients", 
      "subtypes", 
      "cell development", 
      "inhibitors", 
      "tyrosine kinase", 
      "kit", 
      "alterations", 
      "sunitinib", 
      "imatinib", 
      "nilotinib", 
      "L576P", 
      "tumors", 
      "dasatinib", 
      "BRAF", 
      "disease", 
      "trials", 
      "skin", 
      "inhibition", 
      "guidelines", 
      "mutations", 
      "development", 
      "subset", 
      "kinase", 
      "differentiation", 
      "study", 
      "update", 
      "current research", 
      "combination", 
      "success", 
      "growth", 
      "efforts", 
      "incorporation", 
      "research", 
      "model", 
      "development efforts", 
      "drivers"
    ], 
    "name": "KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development", 
    "pagination": "315-323", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111836770"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40257-018-0414-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30707374"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40257-018-0414-1", 
      "https://app.dimensions.ai/details/publication/pub.1111836770"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_805.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40257-018-0414-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40257-018-0414-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40257-018-0414-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40257-018-0414-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40257-018-0414-1'


 

This table displays all metadata directly associated to this object as RDF triples.

238 TRIPLES      21 PREDICATES      115 URIs      95 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40257-018-0414-1 schema:about N07cb323eddcf4161a8cde1f22a9addd1
2 N2d3edc32d1d54a57b7c9d7d67a445811
3 N360d3bc1e1f24da3a471e0c9e7951bdb
4 N64cb2d9403ef4c9f975726367e591ab5
5 N6beb7f8c71cb4639a3cb54b6f108f5a3
6 N7fa93c5056ad4bd48acf95e7becbcca6
7 Na280daa889ae42df81e48bfe6a786646
8 Na96e0646a81d4d65917a522b3b6dab42
9 Ncac5643ba90744b6aa8bb13818889ba9
10 Ncf329fb95baf41d98550b40fe5f07769
11 Ne1e8a24118af4840a67b90288347b512
12 Neafb310ee68042adb0320c1d51ed5c0d
13 Nec4480caecc540a09c5561712f2aec1f
14 Nf512b6939f734e03904786107480529c
15 anzsrc-for:11
16 anzsrc-for:1112
17 schema:author N3d5f9380c98c4c73b40c785eb57534c8
18 schema:citation sg:pub.10.1007/s00018-004-4189-6
19 sg:pub.10.1007/s12185-010-0692-8
20 sg:pub.10.1038/373347a0
21 sg:pub.10.1038/leu.2009.46
22 sg:pub.10.1038/leu.2010.11
23 sg:pub.10.1038/nature00766
24 sg:pub.10.1038/nature11071
25 sg:pub.10.1038/nature22071
26 sg:pub.10.1038/ng.2359
27 sg:pub.10.1038/ng.3382
28 sg:pub.10.1038/nm.2438
29 sg:pub.10.1186/s40425-017-0238-1
30 schema:datePublished 2019-02-01
31 schema:datePublishedReg 2019-02-01
32 schema:description Metastatic melanoma is a heterogenous disease that has served as a model for the development of both targeted therapy and immunotherapy. KIT-mutated melanoma represents a rare subset, most commonly arising from acral, mucosal, and chronically sun-damaged skin. Additionally, KIT alterations are enriched in the triple wild-type subtype of cutaneous melanoma. Activating alterations of KIT—a transmembrane receptor tyrosine kinase important for cell development, growth, and differentiation—have been shown to be critical to oncogenesis across many tumor subtypes. Following the successes of BRAF-targeted therapy in melanoma and KIT-targeted therapy in gastrointestinal stromal tumors, small-molecule tyrosine kinase inhibitors targeting KIT have been examined in KIT-mutated melanoma. KIT inhibitors that have been investigated in relevant clinical trials in advanced melanoma include imatinib, sunitinib, dasatinib, and nilotinib. In these studies, selected patients with KIT-mutated melanoma were shown to be responsive to therapy with KIT inhibition, especially patients with L576P and K642E mutations. This has led to the incorporation of KIT-targeted therapy in the National Comprehensive Cancer Network guidelines for systemic therapy for metastatic or unresectable melanoma. Current research and development efforts include novel KIT-targeted therapies and testing KIT inhibitors in combination with immunotherapy.
33 schema:genre article
34 schema:isAccessibleForFree false
35 schema:isPartOf N5051c57c038e4746a59f150758916df5
36 N8c16848d11fd4ea28397098de696f8c7
37 sg:journal.1021743
38 schema:keywords BRAF
39 KIT alterations
40 KIT inhibition
41 KIT inhibitors
42 L576P
43 National Comprehensive Cancer Network guidelines
44 Network guidelines
45 advanced melanoma
46 alterations
47 cell development
48 clinical development
49 clinical trials
50 combination
51 current research
52 cutaneous melanoma
53 dasatinib
54 development
55 development efforts
56 differentiation
57 disease
58 drivers
59 efforts
60 gastrointestinal stromal tumors
61 growth
62 guidelines
63 heterogenous disease
64 imatinib
65 immunotherapy
66 incorporation
67 inhibition
68 inhibitors
69 kinase
70 kinase inhibitors
71 kit
72 melanoma
73 metastatic melanoma
74 model
75 mutations
76 nilotinib
77 novel kit
78 oncogenic drivers
79 patients
80 rare subset
81 receptor tyrosine kinases
82 relevant clinical trials
83 research
84 skin
85 small molecule tyrosine kinase inhibitors
86 stromal tumors
87 study
88 subset
89 subtypes
90 success
91 sunitinib
92 systemic therapy
93 therapy
94 transmembrane receptor tyrosine kinase
95 trials
96 tumor subtypes
97 tumors
98 tyrosine kinase
99 tyrosine kinase inhibitors
100 unresectable melanoma
101 update
102 schema:name KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development
103 schema:pagination 315-323
104 schema:productId N56618c7988644aaa9255646dc13beec9
105 N7e9aef2c5fbf4b3ab2dd008ab1d16f7c
106 N91fd618e20a24873ae992a63a4442feb
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111836770
108 https://doi.org/10.1007/s40257-018-0414-1
109 schema:sdDatePublished 2022-12-01T06:40
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher N7a7270e9e1fa4405992c86990577269a
112 schema:url https://doi.org/10.1007/s40257-018-0414-1
113 sgo:license sg:explorer/license/
114 sgo:sdDataset articles
115 rdf:type schema:ScholarlyArticle
116 N07cb323eddcf4161a8cde1f22a9addd1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Molecular Targeted Therapy
118 rdf:type schema:DefinedTerm
119 N2d3edc32d1d54a57b7c9d7d67a445811 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Practice Guidelines as Topic
121 rdf:type schema:DefinedTerm
122 N360d3bc1e1f24da3a471e0c9e7951bdb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Treatment Outcome
124 rdf:type schema:DefinedTerm
125 N3d5f9380c98c4c73b40c785eb57534c8 rdf:first Nedbfdbe052ea4e3fb53d000d9456228a
126 rdf:rest Nf72f9151cc7046d28941dfed66548dd4
127 N5051c57c038e4746a59f150758916df5 schema:volumeNumber 20
128 rdf:type schema:PublicationVolume
129 N56618c7988644aaa9255646dc13beec9 schema:name pubmed_id
130 schema:value 30707374
131 rdf:type schema:PropertyValue
132 N64cb2d9403ef4c9f975726367e591ab5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Antineoplastic Combined Chemotherapy Protocols
134 rdf:type schema:DefinedTerm
135 N6beb7f8c71cb4639a3cb54b6f108f5a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Humans
137 rdf:type schema:DefinedTerm
138 N7a7270e9e1fa4405992c86990577269a schema:name Springer Nature - SN SciGraph project
139 rdf:type schema:Organization
140 N7e9aef2c5fbf4b3ab2dd008ab1d16f7c schema:name dimensions_id
141 schema:value pub.1111836770
142 rdf:type schema:PropertyValue
143 N7fa93c5056ad4bd48acf95e7becbcca6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Carcinogenesis
145 rdf:type schema:DefinedTerm
146 N8c16848d11fd4ea28397098de696f8c7 schema:issueNumber 3
147 rdf:type schema:PublicationIssue
148 N91fd618e20a24873ae992a63a4442feb schema:name doi
149 schema:value 10.1007/s40257-018-0414-1
150 rdf:type schema:PropertyValue
151 Na280daa889ae42df81e48bfe6a786646 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Protein Kinase Inhibitors
153 rdf:type schema:DefinedTerm
154 Na96e0646a81d4d65917a522b3b6dab42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Clinical Trials as Topic
156 rdf:type schema:DefinedTerm
157 Ncac5643ba90744b6aa8bb13818889ba9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Dermatology
159 rdf:type schema:DefinedTerm
160 Ncf329fb95baf41d98550b40fe5f07769 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Medical Oncology
162 rdf:type schema:DefinedTerm
163 Ne1e8a24118af4840a67b90288347b512 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Proto-Oncogene Proteins c-kit
165 rdf:type schema:DefinedTerm
166 Neafb310ee68042adb0320c1d51ed5c0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Antineoplastic Agents, Immunological
168 rdf:type schema:DefinedTerm
169 Nec4480caecc540a09c5561712f2aec1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Skin Neoplasms
171 rdf:type schema:DefinedTerm
172 Nedbfdbe052ea4e3fb53d000d9456228a schema:affiliation grid-institutes:grid.21729.3f
173 schema:familyName Meng
174 schema:givenName Da
175 rdf:type schema:Person
176 Nf512b6939f734e03904786107480529c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Melanoma
178 rdf:type schema:DefinedTerm
179 Nf72f9151cc7046d28941dfed66548dd4 rdf:first sg:person.0726366600.25
180 rdf:rest rdf:nil
181 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
182 schema:name Medical and Health Sciences
183 rdf:type schema:DefinedTerm
184 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
185 schema:name Oncology and Carcinogenesis
186 rdf:type schema:DefinedTerm
187 sg:journal.1021743 schema:issn 1175-0561
188 1179-1888
189 schema:name American Journal of Clinical Dermatology
190 schema:publisher Springer Nature
191 rdf:type schema:Periodical
192 sg:person.0726366600.25 schema:affiliation grid-institutes:grid.516091.a
193 schema:familyName Carvajal
194 schema:givenName Richard D.
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25
196 rdf:type schema:Person
197 sg:pub.10.1007/s00018-004-4189-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015934344
198 https://doi.org/10.1007/s00018-004-4189-6
199 rdf:type schema:CreativeWork
200 sg:pub.10.1007/s12185-010-0692-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016450622
201 https://doi.org/10.1007/s12185-010-0692-8
202 rdf:type schema:CreativeWork
203 sg:pub.10.1038/373347a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050917690
204 https://doi.org/10.1038/373347a0
205 rdf:type schema:CreativeWork
206 sg:pub.10.1038/leu.2009.46 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012226579
207 https://doi.org/10.1038/leu.2009.46
208 rdf:type schema:CreativeWork
209 sg:pub.10.1038/leu.2010.11 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046949857
210 https://doi.org/10.1038/leu.2010.11
211 rdf:type schema:CreativeWork
212 sg:pub.10.1038/nature00766 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023536940
213 https://doi.org/10.1038/nature00766
214 rdf:type schema:CreativeWork
215 sg:pub.10.1038/nature11071 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015512980
216 https://doi.org/10.1038/nature11071
217 rdf:type schema:CreativeWork
218 sg:pub.10.1038/nature22071 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085123990
219 https://doi.org/10.1038/nature22071
220 rdf:type schema:CreativeWork
221 sg:pub.10.1038/ng.2359 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021618497
222 https://doi.org/10.1038/ng.2359
223 rdf:type schema:CreativeWork
224 sg:pub.10.1038/ng.3382 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041262840
225 https://doi.org/10.1038/ng.3382
226 rdf:type schema:CreativeWork
227 sg:pub.10.1038/nm.2438 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005333082
228 https://doi.org/10.1038/nm.2438
229 rdf:type schema:CreativeWork
230 sg:pub.10.1186/s40425-017-0238-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084612708
231 https://doi.org/10.1186/s40425-017-0238-1
232 rdf:type schema:CreativeWork
233 grid-institutes:grid.21729.3f schema:alternateName Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA
234 schema:name Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA
235 rdf:type schema:Organization
236 grid-institutes:grid.516091.a schema:alternateName Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center and the Herbert Irving Comprehensive Cancer Center, New York, NY, USA
237 schema:name Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center and the Herbert Irving Comprehensive Cancer Center, New York, NY, USA
238 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...